Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor

European Journal of Cancer

Volumn 48, Issue 10, 2012, Pages 1476-1483

  Bamias, A ^a   Sotiropoulou, M ^b   Zagouri, F ^a   Trachana, P ^a   Sakellariou, K ^a   Kostouros, E ^a   Kakoyianni, K ^a   Rodolakis, A ^a   Vlahos, G ^a   Haidopoulos, D ^a   Thomakos, N ^a   Antsaklis, A ^a   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

Cell type; Grade; Ovarian cancer; Tumour type

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862003959     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.023     Document Type: Article

References (36)

1. I.M. Shih, and R.J. Kurman Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis Am J Pathol 164 2004 1151 1518
2. C.N. Landen, M.J. Birrer, and A.K. Sood Early events in the pathogenesis of epithelial ovarian cancer J Clin Oncol 26 2008 995 1005
3. R. Vang, I.M. Shih, and J. Kurman Ovarian low-grade and high-grade serous carcinoma. Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems Adv Anat Pathol 16 2009 267 282
4. M. Kobel, S.E. Kalloger, and J. Carrick A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary Am J Surg Pathol 33 2009 14 21
5. C.B. Gilks, D.N. Ionescu, and S.E. Kalloger Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian cancer Human Pathol 39 2008 1239 1251
6. A. Bamias, T. Psaltopoulou, and M. Sotiropoulou Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy Cancer 116 2010 1462 1468
7. J. Alexandre, I. Ray-Coquard, and F. Selle Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel- based chemotherapy, the GINECO experience Ann Oncol 21 2010 2377 2381
8. R.J. Zaino, M.F. Brady, and S.M. Lele Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study Cancer 117 2011 554 562
9. A. Du Bois, A. Reuss, and E. Pujade-Lauraine Role of surgical outcome as a prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis analysis of 3 prospectively randomized phase III trials Cancer 115 2009 1234 1244
10. I. Vergote, C. Trope, and F. Amant Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer New Engl J Med 363 2010 943 953
11. M. Kobel, S.E. Kalloger, and J.L. Santos Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications Gynecol Oncol 116 2010 50 56
12. S.G. Silveberg Histopathological grading of ovarian carcinoma: a review and proposal Int J Gynecol Pathol 19 2000 7 15
13. N. Singh, A. Ayhan, and U. Menon Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems Histopathology 52 2008 393 395
14. S. Kommoss, D. Schmidt, and F. Kommoss Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol) Virchows Arch 454 2009 249 256
15. W.E. Winter 3rd, G.L. Maxwell, and C. Tian Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627
16. D. Pectasides, G. Fountzilas, and G. Aravantinos Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience Gynecol Oncol 102 2006 285 291
17. F.A. Tavassoli, and P. Devilee World Health Organization classification of tumours: pathology and genetics. Tumours of the breast and female genital organs 2003 IARC Press Lyon, France
18. International Federation of Gynecology and Obstetrics Classification and staging of malignant tumors in the female pelvis Acta Obstet Gynecol Scand 50 1971 1 7
19. A. Malpica, M.T. Deavers, and K. Lu Grading of ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
20. R. Vang, R. Shih, and E. Sugar Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data Am J Surg Pathol 32 2008 1667 1674
21. R.J. Kurman, and I.M. Shih The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Am J Surg Pathol 34 2010 433 443
22. R.J. Kurman, and I. Shih Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 2008 151 160
23. K.M. Schmeler, C.C. Sun, and D.C. Bodurka Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum Gynecol Oncol 108 2008 510 514
24. D.M. Gershenson, C.C. Sun, and D. Bodurka Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant Gynecol Oncol 114 2009 48 52
25. M.J. Piccart, K. Bertelsen, and K. James Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 2000 699 708
26. A. du Bois, H.J. Lück, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
27. P.A. Shaw, J.R. McLaughlin, and R.P. Zweemer Histopathologic features of genetically determined ovarian cancer Int J Gynecol Pathol 21 2002 407 411
28. R.A. Soslow Histologic subtypes of ovarian carcinoma: an overview Int J Gynecol Pathol 27 2008 161 174
29. A. Bamias, A. Karadimou, and N. Soupos Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience Gynecol Oncol 123 2011 37 42
30. N. Sato, H. Tsunoda, and M. Nishida Loss of heterozygosity on 10pq23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence from benign endometrial cyst to endometrioid carcinomas and clear-cell carcinoma of the ovary Cancer Res 60 2000 7052 7056
31. K.M. Francis-Thickpenny, D.M. Richardson, and C.C. van Ee Analysis of TGF-beta functional pathway in epithelial ovarian carcinoma Br J Cancer 85 2001 687 691
32. S. Jones, T.L. Wang, and IeM Shih Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 330 2010 228 231
33. J.D. Seidman, A.V. Yelemanova, and F. Khedmati Prognostic factors for stage I ovarian carcinoma Int J Gynecol Pathol 29 2010 1 7
34. A. Ayhan, R.J. Kurman, and R. Vang Defining the cut-point between low- and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis Am J Surg Pathol 33 2009 1220 1224
35. A. Malpica, M.T. Deavers, and C. Tornos Interobserver and intraobserver variability of a two-tier system for grading of ovarian serous carcinomas Am J Surg Pathol 31 2007 1168 1174
36. M. Köbel, S.E. Kalloger, and P.M. Baker Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study Am J Surg Pathol 34 2010 984 993